Taro Pharmaceutical Industries Ltd. Ordinary Shares (TARO): Price and Financial Metrics
Taro Pharmaceutical Industries Ltd. Ordinary Shares (TARO)
Today's Latest Price: $67.45 USD
Updated Jul 2 4:10pm
Add TARO to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 214 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
TARO Stock Summary
- Taro Pharmaceutical Industries Ltd's stock had its IPO on April 1, 1993, making it an older stock than 77.77% of US equities in our set.
- The ratio of debt to operating expenses for Taro Pharmaceutical Industries Ltd is higher than it is for about merely 0.34% of US stocks.
- TARO's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 9.37% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Taro Pharmaceutical Industries Ltd are OPTT, AMSC, CBLI, SPNS, and SCON.
- Visit TARO's SEC page to see the company's official filings. To visit the company's web site, go to www.taro.com.
TARO Stock Price Chart Technical Analysis Charts
TARO Price/Volume Stats
| Current price | $67.45 | 52-week high | $99.69 |
| Prev. close | $67.49 | 52-week low | $56.07 |
| Day low | $67.36 | Volume | 21,429 |
| Day high | $68.11 | Avg. volume | 43,356 |
| 50-day MA | $67.51 | Dividend yield | N/A |
| 200-day MA | $75.28 | Market Cap | 2.58B |
Taro Pharmaceutical Industries Ltd. Ordinary Shares (TARO) Company Bio
Taro Pharmaceutical Industries offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. The company was founded in 1959 and is based in Haifa Bay, Israel.
TARO Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $67.45 | $32.85 | -51% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Taro Pharmaceutical Industries Ltd. To summarize, we found that Taro Pharmaceutical Industries Ltd ranked in the 30th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for TARO, they are:
- In the past 4.97 years, Taro Pharmaceutical Industries Ltd has a compound free cash flow growth rate of -0.09%; that's higher than only 11.24% of free cash flow generating stocks in the Healthcare sector.
- The business' balance sheet reveals debt to be 0% of the company's capital (with equity being the remaining amount). Approximately merely 0% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- Taro Pharmaceutical Industries Ltd's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -5.14. This coverage rate is greater than that of only 11.29% of stocks we're observing for the purpose of forecasting via discounted cash flows.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -52% |
| 1% | -52% |
| 2% | -51% |
| 3% | -51% |
| 4% | -50% |
| 5% | -50% |
NUVA, BIO, ZBH, CAH, and IONS can be thought of as valuation peers to TARO, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...